KWBT SEC-arkiveringer - Kiwa Bio-Tech Products Group Corp.- Årsrapport, Fullmaktsdokument, Prospekt

Grunnleggende statistikk

CIK

1159275

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Kiwa Bio-Tech Products Group Corp.

SEC Filings (Chronological Order)

På denne siden finner du en fullstendig, kronologisk liste over SEC-arkiveringer, med unntak av eierskaps-arkiveringer som vi leverer andre steder.

October 3, 2022	EX-10.2	Shareholders’s Voting Rights Designation Agreement, dated as of September 25, 2022, by and between the Feng Li, Yvonne Wang and Wei Li and Xiao Man International Holdings Co., Ltd. Exhibit 10.2 Appendix 1: Shareholder Voting Proxy Agreement This Shareholder Voting Proxy Agreement (hereinafter referred to as ?the Agreement?) is signed among the following parties on September 25, 2022 in [Chengdu], China. Party A: XIAO MAN INTERNATIONAL HOLDINGS CO., LTD., a limited company that is incorporated and exists under the laws of [BRITISH VIRGIN ISLANDS]. Address: [CRAIGMUIR CHAMBERS
October 3, 2022	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 30, 2022 (September 25, 2022) Kiwa Bio-Tech Products Group Corporation (Exact Name of Registrant as Specified in Charter) Nevada 000-33167 77-0632186 (State or Other Jurisdi
October 3, 2022	EX-10.1	Translation of the Coopeartion Agreement, dated as of September 25, 2022, by and between the Feng Li, Yvonne Wang and Wei Li and Xiao Man International Holdings Co., Ltd. Exhibit 10.1 Confidential Cooperation Agreement Between Feng LI, Yvonne WANG, Wei LI and Xiao Man International Holdings Co., Ltd. -1- This Cooperation Agreement (hereinafter referred to as ?the Agreement?) is signed among the following parties on [September 25], 2022 (hereinafter referred to as ?the signing date?). 1. FENG LI, a Chinese natural person. ID number: [110102198812080422], contact add
April 26, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 26, 2021 Kiwa Bio-Tech Products Group Corporation (Exact Name of Registrant as Specified in Charter) Nevada 000-33167 77-0632186 (State or Other Jurisdiction (Commission (IRS Em
February 8, 2021	8-K	Financial Statements and Exhibits 8-K 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 8, 2021 Kiwa Bio-Tech Products Group Corporation (Exact Name of Registrant as Specified in Charter) Nevada 000-33167 77-0632186 (State or Other Jurisdiction
January 26, 2021	8-K	Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 26, 2021 Kiwa Bio-Tech Products Group Corporation (Exact Name of Registrant as Specified in Charter) Nevada 000-33167 77-0632186 (State or Other Jurisdiction of Incorporation)
January 26, 2021	EX-16.1	Letter to SEC from Friedman L.L.P. dated January 25, 2021 Exhibit 16.1 January 25, 2021 Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Kiwa Bio-Tech Products Group Corp. CIK No: 0001159275 Dear Sir or Madam: We have read Form 8-K dated January 25, 2021 of Kiwa Bio-Tech Products Group Corp. (“Registrant”) and are in agreement with the statements contained therein as it pertains to our firm. We have no basis to agree or di
June 1, 2020	10-K/A	Annual Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A First Amendment [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-33167 KIW
May 29, 2020	10-K	Annual Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-33167 KIWA BIO-TECH PRODUCT
May 14, 2020	NT 10-K	- NT 10-K 1 formnt10-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 Commission File Number 000-33167 NOTIFICATION OF LATE FILING (Check One): [X] Form 10-K [ ] Form 11-K [ ] Form 20-F [ ] Form 10-Q [ ] Form N-SAR For Period Ended: December 31, 2019 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 10-Q [ ] Transition Report on Form 20-F [ ] Tra
May 8, 2020	8-K/A	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A Third Amendment CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 6, 2020 Kiwa Bio-Tech Products Group Corporation (Exact Name of Registrant as Specified in Charter) Nevada 000-33167 77-0632186 (State or Other Jurisdiction (C
May 8, 2020	8-K/A	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 6, 2020 Kiwa Bio-Tech Products Group Corporation (Exact Name of Registrant as Specified in Charter) Nevada 000-33167 77-0632186 (State or Other Jurisdiction (Commission (IRS E
April 30, 2020	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 30, 2020 Kiwa Bio-Tech Products Group Corporation (Exact Name of Registrant as Specified in Charter) Nevada 000-33167 77-0632186 (State or Other Jurisdiction (Commission (IRS Em
April 28, 2020	8-K	Entry into a Material Definitive Agreement 8-K 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 28, 2020 Kiwa Bio-Tech Products Group Corporation (Exact Name of Registrant as Specified in Charter) Nevada 000-33167 77-0632186 (State or Other Jurisdiction (
April 3, 2020	DEF 14C	KWBT / Kiwa Bio-Tech Products Group Corp. DEF 14C - - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14C (RULE 14C-101) SCHEDULE 14C INFORMATION INFORMATION STATEMENT PURSUANT TO SECTION 14(C) OF THE SECURITIES EXCHANGE ACT OF 1934 Check the appropriate box: [ ] Preliminary Information Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-5(d) (1)) [X] Definitive Information Statement K
April 1, 2020	CORRESP	- Kiwa Bio-Tech Products Group Corporation 3200 Guasti Road, Suite #100 Ontario, CA 91761 March 31, 2020 VIA EDGAR United States Securities and Exchange Commission Division of Corporate Finance Office of Life Sciences 100 F Street, N.
April 1, 2020	PRER14C	KWBT / Kiwa Bio-Tech Products Group Corp. PRER14C - - PRER14C 1 formprer14c.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14C/A (Second Amendment) (RULE 14C-101) SCHEDULE 14C INFORMATION INFORMATION STATEMENT PURSUANT TO SECTION 14(C) OF THE SECURITIES EXCHANGE ACT OF 1934 Check the appropriate box: [X] Preliminary Information Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-5
March 30, 2020	8-K/A	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 6, 2020 Kiwa Bio-Tech Products Group Corporation (Exact Name of Registrant as Specified in Charter) Nevada 000-33167 77-0632186 (State or Other Jurisdiction (Commission (IRS E
March 20, 2020	PRER14C	KWBT / Kiwa Bio-Tech Products Group Corp. PRER14C - - PRER14C 1 prer14c.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14C/A (First Amendment) (RULE 14C-101) SCHEDULE 14C INFORMATION INFORMATION STATEMENT PURSUANT TO SECTION 14(C) OF THE SECURITIES EXCHANGE ACT OF 1934 Check the appropriate box: [X] Preliminary Information Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-5(d) (
March 18, 2020	PRE 14C	KWBT / Kiwa Bio-Tech Products Group Corp. PRE 14C - - PRE 14C 1 pre14c.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14C (RULE 14C-101) SCHEDULE 14C INFORMATION INFORMATION STATEMENT PURSUANT TO SECTION 14(C) OF THE SECURITIES EXCHANGE ACT OF 1934 Check the appropriate box: [X] Preliminary Information Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-5(d) (1)) [ ] Definitive In
March 6, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 4, 2020 Kiwa Bio-Tech Products Group Corporation (Exact Name of Registrant as Specified in Charter) Nevada 000-33167 77-0632186 (State or Other Jurisdiction of Incorporation) (C
March 6, 2020	8-K	Other Events 8-K 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 6, 2020 Kiwa Bio-Tech Products Group Corporation (Exact Name of Registrant as Specified in Charter) Nevada 000-33167 77-0632186 (State or Other Jurisdiction (C
February 13, 2020	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 5, 2020 Kiwa Bio-Tech Products Group Corporation (Exact Name of Registrant as Specified in Charter) Nevada 000-33167 77-0632186 (State or Other Jurisdiction (Commission (IRS
November 14, 2019	10-Q	KWBT / Kiwa Bio-Tech Products Group Corp. 10-Q - Quarterly Report - 10-Q 1 form10-q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2019 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-3
November 12, 2019	DEF 14C	KWBT / Kiwa Bio-Tech Products Group Corp. DEF 14C - - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14C (RULE 14C-101) SCHEDULE 14C INFORMATION INFORMATION STATEMENT PURSUANT TO SECTION 14(C) OF THE SECURITIES EXCHANGE ACT OF 1934 Check the appropriate box: [ ] Preliminary Information Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-5(d) (1)) [X] Definitive Information Statement K
October 23, 2019	PRE 14C	KWBT / Kiwa Bio-Tech Products Group Corp. PRE 14C - - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14C (RULE 14C-101) SCHEDULE 14C INFORMATION INFORMATION STATEMENT PURSUANT TO SECTION 14(C) OF THE SECURITIES EXCHANGE ACT OF 1934 Check the appropriate box: [X] Preliminary Information Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-5(d) (1)) [ ] Definitive Information Statement K
October 17, 2019	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 7, 2019 Kiwa Bio-Tech Products Group Corporation (Exact Name of Registrant as Specified in Charter) Nevada 000-33167 77-0632186 (State or Other Jurisdiction (Commission (IRS E
October 17, 2019	EX-10.2	Convertible Promissory Note with Geneva Roth Remark Holdings, Inc. dated October 7, 2019
October 17, 2019	EX-10.1	Securities Purchase Agreement between the company and Geneva Roth Remark Holdings, Inc. dated October 7, 2019
October 17, 2019	EX-10.4	Senior Convertible Promissory Note with Morningview Financial, LLC. dated October 7, 2019 NEITHER THE ISSUANCE NOR SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS.
October 17, 2019	EX-10.3	Securities Purchase Agreement between the company and Morningview Financial, LLC. dated October 7, 2019 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of October 7, 2019, by and between KIWA BIO-TECH PRODUCTS GROUP CORPORATION, a Nevada corporation, with headquarters located at 3200 Guasti Road, Suite #100, Ontario, CA 91761 (the “Company”), and MORNINGVIEW FINANCIAL, LLC, a Wyoming limited liability company, with its address at 401 Park Ave.
September 24, 2019	EX-10.1	Securities Purchase Agreement between the company and EMA Financial, LLC dated September 12, 2019 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of September 12, 2019, is entered into by and between Kiwa Bio-Tech Products Group Corporation, a Nevada corporation (the “Company”), and EMA Financial, LLC, a Delaware limited liability company (the “Purchaser”).
September 24, 2019	EX-10.4	Convertible Promissory Note with Firstfire Global Opportunities Fund LLC dated September 19, 2019 THIS INSTRUMENT CONTAINS AN AFFIDAVIT OF CONFESSION OF JUDGMENT PROVISION WHICH CONSTITUTES A WAIVER OF IMPORTANT RIGHTS BORROWER MAY HAVE AND ALLOWS THE HOLDER TO OBTAIN A JUDGMENT AGAINST BORROWER WITHOUT ANY FURTHER NOTICE.
September 24, 2019	EX-10.2	Convertible Promissory Note with EMA Financial, LLC dated September 12, 2019 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS.
September 24, 2019	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 20, 2019 Kiwa Bio-Tech Products Group Corporation (Exact Name of Registrant as Specified in Charter) Nevada 000-33167 77-0632186 (State or Other Jurisdicti
September 24, 2019	EX-10.3	Securities Purchase Agreement between the company and Firstfire Global Opportunities Fund LLC dated September 19, 2019 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of September 19, 2019, by and between KIWA BIO-TECH PRODUCTS GROUP CORPORATION, a Nevada corporation, with headquarters located at 3200 Guasti Road, Suite #100, Ontario, CA 91761 (the “Company”), and FIRSTFIRE GLOBAL OPPORTUNITIES FUND, LLC, a Delaware limited liability company, with its address at 1040 First Avenue, Suite 190, New York, NY 10022 (the “Buyer”).
August 19, 2019	10-Q	KWBT / Kiwa Bio-Tech Products Group Corp. 10-Q - Quarterly Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2019 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-33167 KIWA BIO-TECH PRODUC
August 14, 2019	NT 10-Q	KWBT / Kiwa Bio-Tech Products Group Corp. NT 10-Q - - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 Commission File Number 000-33167 NOTIFICATION OF LATE FILING (Check One): [ ] Form 10-K [ ] Form 11-K [ ] Form 20-F [X] Form 10-Q [ ] Form N-SAR For Period Ended: June 30, 2019 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 10-Q [ ] Transition Report on Form 20-F [ ] Transition Report on Form N-SAR [ ] Transition Report on Form 11-K For Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
July 8, 2019	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits 8-K 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 8, 2019 Kiwa Bio-Tech Products Group Corporation (Exact Name of Registrant as Specified in Charter) Nevada 000-33167 77-0632186 (State or Other Jurisdiction of
May 15, 2019	10-Q	KWBT / Kiwa Bio-Tech Products Group Corp. 10-Q Quarterly Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2019 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-33167 KIWA BIO-TECH PRODU
April 12, 2019	10-K	KWBT / Kiwa Bio-Tech Products Group Corp. (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-33167 KIWA BIO-TECH PRODUCT
April 1, 2019	NT 10-K	KWBT / Kiwa Bio-Tech Products Group Corp. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 Commission File Number 000-33167 NOTIFICATION OF LATE FILING (Check One): [X] Form 10-K [ ] Form 11-K [ ] Form 20-F [ ] Form 10-Q [ ] Form N-SAR For Period Ended: December 31, 2018 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 10-Q [ ] Transition Report on Form 20-F [ ] Transition Report on Form N-SAR [ ] Transition Report on Form 11-K For Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
March 18, 2019	10-Q/A	KWBT / Kiwa Bio-Tech Products Group Corp. (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment No. 3 [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2017 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-33167 K
March 15, 2019	10-Q/A	KWBT / Kiwa Bio-Tech Products Group Corp. (Quarterly Report) 10-Q/A 1 form10-qa.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment No. 2 [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2017 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission Fi
March 15, 2019	10-Q/A	KWBT / Kiwa Bio-Tech Products Group Corp. (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment No. 1 [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2017 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-33167 KI
March 15, 2019	10-Q/A	KWBT / Kiwa Bio-Tech Products Group Corp. (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment No. 2 [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2017 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-33167 K
March 7, 2019	EX-10.1	Securities Purchase Agreement between the company and Labrys Fund, LP dated February 27, 2019
March 7, 2019	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 27, 2019 Kiwa Bio-Tech Products Group Corporation (Exact Name of Registrant as Specified in Charter) Nevada 000-33167 77-0632186 (State or Other Jurisdiction (Commission (IRS
March 7, 2019	EX-10.2	Convertible Promissory Note with Labrys Fund, LP dated February 27, 2019
December 14, 2018	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 14, 2018 Kiwa Bio-Tech Products Group Corporation (Exact Name of Registrant as Specified in Charter) Nevada 000-33167 77-0632186 (State or Other Jurisdictio
November 19, 2018	10-Q	KWBT / Kiwa Bio-Tech Products Group Corp. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2018 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-33167 KIWA BIO-TECH P
November 14, 2018	NT 10-Q	KWBT / Kiwa Bio-Tech Products Group Corp. NT 10-Q NT 10-Q 1 formnt10-q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 Commission File Number 000-33167 NOTIFICATION OF LATE FILING (Check One): [ ] Form 10-K [ ] Form 11-K [ ] Form 20-F [X] Form 10-Q [ ] Form N-SAR For Period Ended: September 30, 2018 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 10-Q [ ] Transition Report on Form 20-F [ ] Tr
October 22, 2018	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 12, 2018 Kiwa Bio-Tech Products Group Corporation (Exact Name of Registrant as Specified in Charter) Nevada 000-33167 77-0632186 (State or Other Jurisdiction
September 28, 2018	EX-10.1	Kiwa Bio-Tech Products Group Corporation 2016 Employee, Director and Consultant Stock Plan. EXHIBIT 10.1 KIWA BIO-TECH PRODUCTS GROUP CORPORATION 2016 EMPLOYEE, DIRECTOR AND CONSULTANT STOCK PLAN PREAMBLE This Plan replaces the 2004 Stock Incentive Plan previously adopted by the Company, which has now expired. 1. DEFINITIONS. Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this Kiwa Bio-Tech Products Group Corporation 2016 Employee, Di
September 28, 2018	S-8	KWBT / Kiwa Bio-Tech Products Group Corp. S-8 S-8 1 forms-8.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Kiwa Bio-Tech Products Group Corporation (Exact name of Registrant as specified in its charter) Nevada 77-0632186 (State or other jurisdiction of Incorporation or organization) (I.R.S. Employer Identification No.) 3200 Guasti Road, Suite 100 Ont
August 17, 2018	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 17, 2018 Kiwa Bio-Tech Products Group Corporation (Exact Name of Registrant as Specified in Charter) Nevada 000-33167 77-0632186 (State or Other Jurisdiction
August 14, 2018	10-Q	KWBT / Kiwa Bio-Tech Products Group Corp. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2018 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-33167 KIWA BIO-TECH PRODUC
July 2, 2018	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 27, 2018 Kiwa Bio-Tech Products Group Corporation (Exact Name of Registrant as Specified in Charter) Nevada 000-33167 77-0632186 (State or Other Jurisdiction of Incorporation) (C
May 14, 2018	10-Q	KWBT / Kiwa Bio-Tech Products Group Corp. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2018 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-33167 KIWA BIO-TECH PRODU
April 17, 2018	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits 8-K 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 16, 2018 Kiwa Bio-Tech Products Group Corporation (Exact Name of Registrant as Specified in Charter) Nevada 000-33167 77-0632186 (State or Other Jurisdiction (
March 30, 2018	10-K	KWBT / Kiwa Bio-Tech Products Group Corp. 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-33167 KIWA BIO-TECH PRODUCT
March 30, 2018	EX-31.	Certification of Chief Executive Officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934 EXHIBIT 31.1 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 (18 U.S.C. SECTION 1350) I, Yvonne Wang, certify that: 1. I have reviewed this Amended Form 10-K for the period ended December 31, 2017 of Kiwa Bio-Tech Products Group Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necess
December 29, 2017	EX-10.1	Subscription and Debt Cancellation Agreement between Kiwa Bio-Tech Products Group Corporation and Wei Li dated December 28, 2017 EXHIBIT 10.1 SUBSCRIPTION AND DEBT CANCELLATION AGREEMENT Series B Redeemable Convertible Preferred Stock of Kiwa Bio-Tech Products Group Corporation The undersigned, Wei Li (the ?Purchaser?), hereby subscribes for the purchase of 811,148 shares (the ?Shares?) of Series B Redeemable Convertible Preferred Stock of Kiwa Bio-Tech Products Group Corporation, a Nevada corporation (the ?Company?), for a
December 29, 2017	EX-4.1	Certificate of Designation for Series B Redeemable Convertible Preferred Stock EXHIBIT 4.1 CERTIFICATE OF DESIGNATION FOR SERIES B REDEEMABLE CONVERTIBLE PREFERRED STOCK Par value $.001 OF KIWA BIO-TECH PRODUCTS GROUP CORPORATION Yvonne Wang and Lucy Li certify that they are the President and Secretary, respectively, of Kiwa Bio-Tech Products Group Corporation, a Nevada corporation (the ?Company?); that, pursuant to the Company?s Articles of Incorporation and applicable Neva
December 29, 2017	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits 8-K 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 28, 2017 Kiwa Bio-Tech Products Group Corporation (Exact Name of Registrant as Specified in Charter) Nevada 000-33167 77-0632186 (State or Other Jurisdictio
December 22, 2017	10-Q	KWBT / Kiwa Bio-Tech Products Group Corp. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2017 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-33167 KIWA BIO-TECH P
November 22, 2017	8-K	Financial Statements and Exhibits, Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 22, 2017 Kiwa Bio-Tech Products Group Corporation (Exact Name of Registrant as Specified in Charter) Nevada 000-33167 77-0632186 (State or Other Jurisdiction (Commission (IRS
November 22, 2017	EX-99.1	Kiwa Files Restated Financial Statements EXHIBIT 99.1 Kiwa Files Restated Financial Statements Ontario, CA? (November 22, 2017) ? On November 22, 2017, following a re-audit of the Company?s Annual Financial Statement for the year ended December 31, 2016 by Friedman LLP, the Company?s new independent registered public accounting firm, the Company filed an amended Annual Report on Form 10-K/A (the ?Amended Annual Report?) with the Securiti
November 22, 2017	10-K/A	KWBT / Kiwa Bio-Tech Products Group Corp. 10-K/A (Annual Report) 10-K/A 1 form10-ka.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-33
November 14, 2017	NT 10-Q	KWBT / Kiwa Bio-Tech Products Group Corp. 0-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 Commission File Number 000-33167 NOTIFICATION OF LATE FILING (Check One): [ ] Form 10-K [ ] Form 11-K [ ] Form 20-F [X] Form 10-Q [ ] Form N-SAR For Period Ended: September 30, 2017 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 10-Q [ ] Transition Report on Form 20-F [ ] Transition Report on Form N-SAR [ ] Transition Report on Form 11-K For Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
October 17, 2017	8-K/A	Financial Statements and Exhibits, Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A Second Amendment CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 11, 2017 Kiwa Bio-Tech Products Group Corporation (Exact Name of Registrant as Specified in Charter) Nevada 000-33167 77-0632186 (State or Other Jurisdictio
October 17, 2017	EX-16.1	Letter from DYH & Company addressed to the U.S. Securities and Exchange Commission dated October 13, 2017.
October 13, 2017	8-K/A	Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 11, 2017 Kiwa Bio-Tech Products Group Corporation (Exact Name of Registrant as Specified in Charter) Nevada 000-33167 77-0632186 (State or Other Jurisdiction of Incorporatio
October 13, 2017	EX-7.1	Letter from DYH & Company addressed to the U.S. Securities and Exchange Commission dated October 13, 2017.
October 13, 2017	EX-16.1	Letter from DYH & Company addressed to the U.S. Securities and Exchange Commission dated October 13, 2017.
October 13, 2017	8-K/A	Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 11, 2017 Kiwa Bio-Tech Products Group Corporation (Exact Name of Registrant as Specified in Charter) Nevada 000-33167 77-0632186 (State or Other Jurisdiction of Incorporatio
October 11, 2017	8-K	Financial Statements and Exhibits, Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 11, 2017 Kiwa Bio-Tech Products Group Corporation (Exact Name of Registrant as Specified in Charter) Nevada 000-33167 77-0632186 (State or Other Jurisdiction (Commission (IRS
October 11, 2017	8-K	Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant, Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 11, 2017 Kiwa Bio-Tech Products Group Corporation (Exact Name of Registrant as Specified in Charter) Nevada 000-33167 77-0632186 (State or Other Jurisdiction of Incorporation)
August 14, 2017	10-Q	KWBT / Kiwa Bio-Tech Products Group Corp. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2017 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-33167 KIWA BIO-TECH PRODUC
May 17, 2017	10-Q/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A 10-Q/A 1 form10-qa.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2017 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-
May 15, 2017	10-Q	Kiwa Bio-Tech Products Group (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2017 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-33167 KIWA BIO-TECH PRODU
May 10, 2017	EX-4.1	KIWA BIO-TECH PRODUCTS GROUP cORP. (NASDAQ OTC: KWBT) junwei zheng convertible LOAN Agreement May 9, 2017 KIWA BIO-TECH PRODUCTS GROUP cORP. (NASDAQ OTC: KWBT) AND junwei zheng convertible LOAN Agreement May 9, 2017 1 This Agreement is dated on May 9, 2017. Between:- (1) KIWA BIO-TECH PRODUCTS GROUP CORPORATION, a company incorporated under the laws of the State of Delaware in the United States of America whose registered office is at 310 N. Indian Hill Blvd., #702, USA (the ?Borrower?); and (2) Junwe
May 10, 2017	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 10, 2017 Kiwa Bio-Tech Products Group Corporation (Exact Name of Registrant as Specified in Charter) Nevada 000-33167 77-0632186 (State or Other Jurisdiction (Co
May 3, 2017	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A First Amendment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A First Amendment [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-33167 KIW
April 17, 2017	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-33167 KIWA BIO-TECH PRODUCT
April 5, 2017	SC 13D	KWBT / Kiwa Bio-Tech Products Group Corp. / Zheng Junwei Activist Investment SC 13D 1 sc13d.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 KIWA BIO-TECH PRODUCTS GROUP CORPORATION (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 49834X 205 (CUSIP Number) Junwei Zheng No. Room 1503 HuichengCommerce Tower No. 839, Xiahe Road Siming District, Xiamen Zip
March 31, 2017	NT 10-K	Kiwa Bio-Tech Products Group 0-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 Commission File Number 000-33167 NOTIFICATION OF LATE FILING (Check One): [X] Form 10-K [ ] Form 11-K [ ] Form 20-F [ ] Form 10-Q [ ] Form N-SAR For Period Ended: December 31, 2016 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 10-Q [ ] Transition Report on Form 20-F [ ] Transition Report on Form N-SAR [ ] Transition Report on Form 11-K For Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
March 15, 2017	EX-4.1	KIWA BIOTECH PRODUCTS GROUP CORPORATION 2016 EMPLOYEE, DIRECTOR AND CONSULTANT STOCK PLAN KIWA BIOTECH PRODUCTS GROUP CORPORATION 2016 EMPLOYEE, DIRECTOR AND CONSULTANT STOCK PLAN PREAMBLE This Plan replaces the 2004 Stock Incentive Plan previously adopted by the Company, which has now expired.
March 15, 2017	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 13, 2017 Kiwa Bio-Tech Products Group Corporation (Exact Name of Registrant as Specified in Charter) Nevada 000-33167 77-0632186 (State or Other Jurisdiction (Commission (IRS Em
March 15, 2017	EX-3.(I)	EX-3.(I)
February 24, 2017	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 15, 2017 Kiwa Bio-Tech Products Group Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-33167 77-0632186 (State or Other Jurisdiction of Incorporati
February 22, 2017	8-K	Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits 8-K 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 15, 2017 Kiwa Bio-Tech Products Group Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-33167 77-0632186 (State or Other Jurisdict
February 17, 2017	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 11, 2017 Kiwa Bio-Tech Products Group Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-33167 77-0632186 (State or Other Jurisdiction (Commission (I
November 21, 2016	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2016 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-33167 KIWA BIO-TECH P
November 15, 2016	NT 10-Q	Kiwa Bio-Tech Products Group 0-Q NT 10-Q 1 nt10-q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 Commission File Number 000-33167 NOTIFICATION OF LATE FILING (Check One): [ ] Form 10-K [ ] Form 11-K [ ] Form 20-F [X] Form 10-Q [ ] Form N-SAR For Period Ended: September 30, 2016 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 10-Q [ ] Transition Report on Form 20-F [ ] Transi
November 2, 2016	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 26, 2016 Kiwa Bio-Tech Products Group Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-33167 77-0632186 (State or Other Jurisdiction (Commission (IR
September 13, 2016	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 7, 2016 Kiwa Bio-Tech Products Group Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-33167 77-0632186 (State or Other Jurisdiction (Comm
August 15, 2016	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2016 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-33167 KIWA BIO-TECH PRODUC
August 15, 2016	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2016 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-33167 KIWA BIO-TECH PRODUC
August 11, 2016	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 11, 2016 Kiwa Bio-Tech Products Group Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-33167 77-0632186 (State or Other Jurisdiction (Commission (IRS
June 20, 2016	SC 13D/A	KWBT / Kiwa Bio-Tech Products Group Corp. / LI WEI Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (Amendment No. 1) Under the Securities Exchange Act of 1934 KIWA BIO-TECH PRODUCTS GROUP CORPORATION (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 49834X 205 (CUSIP Number) Wei Li 310 N. Indian Hill Blvd., #702 Claremont, California 91711 (626) 715-5855 (Name, Address and
May 16, 2016	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2016 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-33167 KIWA BIO-TECH PRODU
May 4, 2016	SC 13D	KWBT / Kiwa Bio-Tech Products Group Corp. / LI WEI Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 KIWA BIO-TECH PRODUCTS GROUP CORPORATION (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 49834X 205 (CUSIP Number) Wei Li 310 N. Indian Hill Blvd., #702 Claremont, California 91711 (626) 715-5855 (Name, Address and Telephone Number
April 14, 2016	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-33167 KIWA BIO-TECH PRODUCT
March 31, 2016	NT 10-K	Kiwa Bio-Tech Products Group 0-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 Commission File Number 000-33167 NOTIFICATION OF LATE FILING (Check One): [X] Form 10-K [ ] Form 11-K [ ] Form 20-F [ ] Form 10-Q [ ] Form N-SAR For Period Ended: December 31, 2015 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 10-Q [ ] Transition Report on Form 20-F [ ] Transition Report on Form N-SAR [ ] Transition Report on Form 11-K For Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
March 24, 2016	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 23, 2016 Kiwa Bio-Tech Products Group Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-33167 77-0632186 (State or Other Jurisdiction (Commission (IRS
March 8, 2016	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 1, 2016 Kiwa Bio-Tech Products Group Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-33167 77-0632186 (State or Other Jurisdiction
January 28, 2016	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 28, 2016 Kiwa Bio-Tech Products Group Corporation (Exact Name of Registrant as Specified in Charter) Delaware 000-33167 77-0632186 (State or Other Jurisdiction (Commission (IR
December 28, 2015	DEF 14C	Kiwa Bio-Tech Products Group 14C UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14C (RULE 14C-101) SCHEDULE 14C INFORMATION INFORMATION STATEMENT PURSUANT TO SECTION 14(C) OF THE SECURITIES EXCHANGE ACT OF 1934 Check the appropriate box: [ ] Preliminary Information Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-5(d) (1)) [X] Definitive Information Statement K
December 17, 2015	8-K	Kiwa Bio-Tech Products Group (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 17, 2015 KIWA BIO-TECH PRODUCTS GROUP CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-33167 77-0632186 (State or other jurisdiction of incorpo
December 17, 2015	EX-99.1	Kiwa Bio-Tech Signed a Distribution Agreement with Kangtan Gerui (Beijing) Bio-Tech Co., Ltd. EX-99.1 3 ex99-1.htm Kiwa Bio-Tech Signed a Distribution Agreement with Kangtan Gerui (Beijing) Bio-Tech Co., Ltd. CLAREMONT, Calif., December 17, 2015 (Marketwired) — Kiwa Bio-Tech Products Group Corporation (OTCBB: KWBT) reported today that it has signed an agreement with Kangtan Gerui (Beijing) Bio-Tech Co., Ltd. and formally awarded distribution and sales rights with respect to Kiwa fertilizer
December 17, 2015	EX-10.1	Cooperation Agreement Cooperation Agreement Party A: Kiwa Bio-Tech Products Group Corporation (hereinafter referred to as Party A).
December 16, 2015	PRE 14C	Kiwa Bio-Tech Products Group 14C UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14C (RULE 14C-101) SCHEDULE 14C INFORMATION INFORMATION STATEMENT PURSUANT TO SECTION 14(C) OF THE SECURITIES EXCHANGE ACT OF 1934 Check the appropriate box: [X] Preliminary Information Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-5(d) (1)) [ ] Definitive Information Statement K
December 15, 2015	EX-10.1	EMPLOYMENT AGREEMENT Exhibit 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT is made and entered into this 15th day of December, 2015 by and between Kiwa Bio-tech Products Group Corp., a Delaware corporation having its principal place of business at 310 N. Indian Hill Blvd., #702 Claremont, California and Yvonne Wang, an individual, whose address is 118 Pistacia Lane, Pomona CA 91711 (?Executive?), with reference
December 15, 2015	8-K	Kiwa Bio-Tech Products Group FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2015 KIWA BIO-TECH PRODUCTS GROUP CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-33167 77-0632186 (State or other jurisdiction of incorpo
December 4, 2015	8-K	Entry into a Material Definitive Agreement 8-K 1 s1023148k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2015 KIWA BIO-TECH PRODUCTS GROUP CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-33167 77-0632186 (State or other
December 4, 2015	EX-10.1	Stock Equity Transfer Agreement Exhibit 10.1 Stock Equity Transfer Agreement Transferer: Jiang Shan Strategic Investment Management Ltd (Hereinafter referred as Co-party A for short) Transferee: Kiwa Bio-Tech Products Group Ltd. (Hereinafter referred as Party B for short) Whereas Co-party A in CABER HOLDINGS LTD company (Hereinafter referred as tender company) legally owns 100% shares of stock equity, (co-party A referred as ten
December 4, 2015	EX-99.1	Kiwa Bio-Tech Products Group Corp. acquired Hong Kong Baina Group Co., Ltd. EX-99.1 3 s102314ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Kiwa Bio-Tech Products Group Corp. acquired Hong Kong Baina Group Co., Ltd. CLAREMONT, Calif., Nov 30, 2015 (Globenewswire) – The board of directors of Kiwa Bio-Tech Products Group Corporation (OTCBB: KWBT) signed an acquisition agreement with Hong Kong Baina Group Co., Ltd. (hereinafter referred to as Baina Hong Kong) to acquire Baina Hong Kon
November 25, 2015	8-K	Submission of Matters to a Vote of Security Holders 8-K 1 s1022698k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2015 KIWA BIO-TECH PRODUCTS GROUP CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-33167 77-0632186 (State or other
November 16, 2015	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q R QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2015 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-33167 KIWA BIO-TECH PRODU
November 10, 2015	EX-10.1	Strategic Cooperation Agreement Exhibit 10.1 Strategic Cooperation Agreement This Agreement is signed by the following parties on November 5th, 2015, in Beijing. Party A: KIWA BIO-TECH PRODUCTS GROUP CORPORATION Representative: Mr. Wei Li Address: 310 N. Indian Hill Blvd., #702, Claremont, California Post code: 91711-4611 Party B: Institute of Agricultural Resources and Regional Planning, CAAS Representative: Mr. Yongchang Wu Ad
November 10, 2015	8-K	Kiwa Bio-Tech Products Group 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2015 KIWA BIO-TECH PRODUCTS GROUP CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-33167 77-0632186 (State or other jurisdiction of incorpor
November 10, 2015	EX-99.1	Kiwa Bio-Tech Signed Strategic Partnership Agreement with the Institute of Agricultural Resources and Regional Planning, the Chinese Academy of Agricultural Sciences (IARRP; CAAS) and the Institute of Agricultural Economics and Development (IAED; CAA EX-99.1 3 v424196ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Kiwa Bio-Tech Signed Strategic Partnership Agreement with the Institute of Agricultural Resources and Regional Planning, the Chinese Academy of Agricultural Sciences (IARRP; CAAS) and the Institute of Agricultural Economics and Development (IAED; CAAS) CLAREMONT, Calif., Nov 10, 2015 (Globenewswire) - Kiwa Bio-Tech Products Group Corporation (O
October 19, 2015	DEF 14A	Kiwa Bio-Tech Products Group DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant To Section 14(A) of the Securities Exchange Act of 1934 Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy Statement ¨ Definitive Additional Materials ¨ Soliciting Mater
October 6, 2015	PRE 14A	Kiwa Bio-Tech Products Group PRELIMINARY PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant To Section 14(A) of the Securities Exchange Act of 1934 Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy Statement ¨ Definitive Additional Materials ¨ Soliciting Mater
August 14, 2015	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.20549 FORM 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2015 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-33167 KIWA BIO-TECH PRODUCTS GR
July 31, 2015	EX-10.1	EMPLOYMENT AGREEMENT Exhibit 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT is made and entered into this 1th day of July, 2015 by and between Kiwa Bio-tech Products Group Corp., a Delaware corporation having its principal place of business at 310 N. Indian Hill Blvd., #702 Claremont, California and Jimmy Ji Zhou, an individual, whose address is 3422 E. Temple Way West Covina, CA 91791 (?Executive?), with referen
July 31, 2015	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.20549 FORM 10-Q R QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2015 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-33167 KIWA BIO-TECH PRODUCTS G
July 7, 2015	EX-10.1	EMPLOYMENT AGREEMENT Exhibit 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT is made and entered into this 1th day of July, 2015 by and between Kiwa Bio-tech Products Group Corp., a Delaware corporation having its principal place of business at 310 N. Indian Hill Blvd., #702 Claremont, California and Jimmy Ji Zhou, an individual, whose address is 3422 E. Temple Way West Covina, CA 91791 (?Executive?), with referen
July 7, 2015	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement 8-K 1 v4149998k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2015 KIWA BIO-TECH PRODUCTS GROUP CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-33167 77-0632186 (State or
June 29, 2015	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2014 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-33167 KIWA BIO-TECH PRODUCTS GR
March 30, 2015	NT 10-K	Kiwa Bio-Tech Products Group FORM 12B-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SEC File Number 000-33167 CUSIP Number: 49834X106 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): x Form 10-K ¨ Form 20-F ¨ Form 11-K ¨ Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: December 31, 2014 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Tr
November 12, 2014	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.20549 FORM 10-Q R QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2014 ¨ TRANSITION REPORT PURSUANT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.20549 FORM 10-Q R QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2014 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-33167 KIWA BIO-TECH PRODUC
August 19, 2014	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.20549 FORM 10-Q R QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2014 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-33167 KIWA BIO-TECH PRODUCTS GR
August 13, 2014	NT 10-Q	KWBT / Kiwa Bio-Tech Products Group Corp. NT 10-Q - - NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: June 30, 2014 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition Report on Form 10-Q ¨ Transition Report on Fo
June 19, 2014	CORRESP	- CORRESP 1 filename1.htm Kiwa Bio-Tech Products Group Corporation 310 N. Indian Hill Boulevard #702 Claremont, California 91711 June 18, 2014 Linda Cvrkel Branch Chief United States Securities and Exchange Commission 100 F Street NE Washington, DC 20549 Re: Kiwa Bio-Tech Products Group Corporation Form 10-K for the year ended December 31, 2013 Filed March 31, 2014 File No. 0-33167 Dear Ms. Cvrkel:
May 20, 2014	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.20549 FORM 10-Q R QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2014 ¨ TRANSITION REPORT PURSUANT TO S UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.20549 FORM 10-Q R QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2014 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-33167 KIWA BIO-TECH PRODUCTS G
May 15, 2014	NT 10-Q	- FORM NT 10-Q NT 10-Q 1 v378772nt10q.htm FORM NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): SEC FILE NUMBER 000-53490 ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: March 31, 2014 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on F
March 31, 2014	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2013 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-33167 KIWA BIO-TECH PRODUCTS GR
November 14, 2013	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q R QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2013 ¨ TRANSITION REPORT PURSUANT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q R QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2013 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-33167 KIWA BIO-TECH PRODU
October 1, 2013	8-K	Termination of a Material Definitive Agreement - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 23, 2013 KIWA BIO-TECH PRODUCTS GROUP CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-33167 77-0632186 (State or other jurisdiction of incorp
October 1, 2013	EX-10.1	EX-10.1 EX-10.1 2 v356116ex10-1.htm EXHIBIT 10.1
August 12, 2013	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.20549 FORM 10-Q R QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2013 £ TRANSITION REPORT PURSUANT TO SE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.20549 FORM 10-Q R QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2013 £ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-33167 KIWA BIO-TECH PRODUCTS GR
May 15, 2013	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2013 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-33167 KIWA BIO-TECH PRODUCTS
April 15, 2013	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2012 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number: 000-33167 KIWA BIO-TECH PRODUCTS GROUP
March 29, 2013	NT 10-K	- FORM 12B-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER: 000-33167 CUSIP NUMBER: 49834X 10 6 (Check One): x Form 10-K ¨ Form 20-F ¨ Form 11-K ¨ Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: December 31, 2012 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨
December 19, 2012	8-K	Submission of Matters to a Vote of Security Holders - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 2012 KIWA BIO-TECH PRODUCTS GROUP CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-33167 77-0632186 (State or other jurisdiction of incorpo
November 13, 2012	DEF 14A	- DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State
November 9, 2012	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.20549 FORM 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2012 ¨ TRANSITION REPORT PURSUANT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2012 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-33167 KIWA BIO-TECH PRODUC
October 15, 2012	PRE 14A	- PRE 14A PRE 14A 1 v325654pre14a.htm PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ý Filed by a Party other than the Registrant ¨ Check the appropriate box: ý Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 1
August 29, 2012	10-Q/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment No. 1 þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2012 ¨ TRANSITION RE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment No. 1 þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2012 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-33167 KIWA B
August 17, 2012	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2012 ¨ TRANSITION REPORT PURSUANT TO S UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2012 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-33167 KIWA BIO-TECH PRODUCTS G
August 13, 2012	NT 10-Q	- FORM NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER: 000-33167 CUSIP NUMBER: 49834X 10 6 (Check One): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form N-SAR ¨ Form N-CSR For Period Ended: June 30, 2012 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition Repo
May 21, 2012	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.20549 FORM 10-Q R QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2012 ¨ TRANSITION REPORT PURSUANT TO S UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.20549 FORM 10-Q R QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2012 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-33167 KIWA BIO-TECH PRODUCTS G
May 14, 2012	NT 10-Q	- FORM 12B-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER: 000-33167 CUSIP NUMBER: 49834X 10 6 (Check One): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form N-SAR ¨ Form N-CSR For Period Ended: March 31, 2012 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition Rep
April 6, 2012	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2011 ¨ TRANSITION REPORT PURSUANT TO SECTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2011 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number: 000-33167 KIWA BIO-TECH PRODUCTS GROUP
March 30, 2012	NT 10-K	- NOTICE UNDER RUEL 12B25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER: 000-33167 CUSIP NUMBER: 49834X 10 6 (Check One): x Form 10-K ¨ Form 20-F ¨ Form 11-K ¨ Form 10-Q ¨ Form N-SAR ¨ Form N-CSR For Period Ended: December 31, 2011 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition
February 6, 2012	EX-10.2	EMPLOYMENT AGREEMENT EX-10.2 3 v301062ex10-2.htm EXHIBIT 10.2 Exhibit 10.2 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT is made and entered into this February 6, 2012 by and between Kiwa Bio-tech Products Group Corp., a Delaware corporation having its principal place of business at 310 N. Indian Hill Blvd., #702 Claremont, California and Steven Ning Ma, an individual, whose address is Room 402, 36 Lane 380, Tianyaoq
February 6, 2012	EX-10.1	EMPLOYMENT AGREEMENT EX-10.1 2 v301062ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT is made and entered into this February 6, 2012 by and between Kiwa Bio-Tech Products Group Corp., a Delaware corporation having its principal place of business at 310 N. Indian Hill Blvd., #702 Claremont, California and Li Wei, an individual, whose address is 6 Hao Lou, #1805, Dao Xiang Yuan, Hai D
February 6, 2012	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2012 KIWA BIO-TECH PRODUCTS GROUP CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-33167 77-0632186 (State or other jurisdiction of incorpor
December 19, 2011	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2011 KIWA BIO-TECH PRODUCTS GROUP CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-33167 77-0632186 (State or other jurisdiction of incorpo
November 10, 2011	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State
November 8, 2011	10-Q	UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.20549 FORM 10-Q R QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2011 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-33167 KIWA BIO-TECH PRODUC
November 8, 2011	EX-10.1	Lease Agreement EX-10.1 2 v238709ex10-1.htm EXHIBIT 10.1 Lease Agreement Party A: Kiwa Bio-Tech Products Group Corporation (“Kiwa”) Party B: Kangtai New Agricultural Technologies Development (Beijing) Co., Ltd. ("Kangtai") Whereas, Party B leases offices locate in Room 1702, Building A Global Trade Center, 36 North Third Ring Road East, Dongcheng District, Beijing, China. Party A leases three rooms as Party A’s o
October 17, 2011	CORRESP	Kiwa Bio-Tech Products Group Corporation 310 N. Indian Hill Boulevard #702 Claremont, California 91711 October 12, 2011 Kiwa Bio-Tech Products Group Corporation 310 N. Indian Hill Boulevard #702 Claremont, California 91711 October 12, 2011 Linda Cvrkel Branch Chief United States Securities and Exchange Commission 100 F Street NE Washington, DC 20549 Re: Kiwa Bio-Tech Products Group Corporation Form 10-K for the year ended December 31, 2010 Filed April 15, 2011 File No. 000-33167 Dear Ms. Cvrkel: This letter respond
October 14, 2011	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State
September 29, 2011	CORRESP	Kiwa Bio-Tech Products Group Corporation 310 N. Indian Hill Boulevard #702 Claremont, California 91711 September 21, 2011 Kiwa Bio-Tech Products Group Corporation 310 N. Indian Hill Boulevard #702 Claremont, California 91711 September 21, 2011 Linda Cvrkel Branch Chief United States Securities and Exchange Commission 100 F Street NE Washington, DC 20549 Re: Kiwa Bio-Tech Products Group Corporation Form 10-K for the year ended December 31, 2010 Filed April 15, 2011 Form 10-Q for the quarter ended March 31, 2011 Filed
August 10, 2011	EX-10.2	Letter of Commitment EX-10.2 3 v230685ex10-2.htm EXHIBIT 10.2 Letter of Commitment Kiwa Bio-Tech Products Group Corporation (the “Company”) is experiencing difficulties in its operations. Management is determined to maintain its operation and remedy the Company’s poor operating results. I, as the Secretary of the Company have been providing financing resources to the Company without any interests. /s/ Yvonne Wang Yvon
August 10, 2011	EX-10.1	Letter of Commitment Letter of Commitment Kiwa Bio-Tech Products Group Corporation (the ?Company?) is experiencing difficulties in its operations.
August 10, 2011	10-Q	UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.20549 FORM 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2011 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-33167 KIWA BIO-TECH PRODUCTS GR
June 16, 2011	8-K	Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2011 KIWA BIO-TECH PRODUCTS GROUP CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-33167 77-0632186 (State or other jurisdiction of incorporati
June 16, 2011	EX-16.1	EX-16.1 EX-16.1 2 v226097ex16-1.htm
May 16, 2011	10-Q	UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.20549 FORM 10-Q R QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2011 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-33167 KIWA BIO-TECH PRODUCTS G
April 15, 2011	10-K	UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2010 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number: 000-33167 KIWA BIO-TECH PRODUCTS GROUP
March 28, 2011	NT 10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number: 000-33167 CUSIP Number: 49834X 10 6 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number: 000-33167 CUSIP Number: 49834X 10 6 (Check One): þ Form 10-K o Form 20-F o Form 11-K o Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: December 31, 2010 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form
December 21, 2010	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2010 KIWA BIO-TECH PRODUCTS GROUP CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-33167 77-0632186 (State or other jurisdiction of incorpo
November 15, 2010	10-Q	UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2010 □ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-33167 KIWA BIO-TECH PRODU
November 5, 2010	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State
October 15, 2010	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State
August 19, 2010	10-Q	UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q R QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2010 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-33167 KIWA BIO-TECH PRODUCTS G
August 13, 2010	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number: 000-33167 CUSIP Number: 49834X 10 6 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number: 000-33167 CUSIP Number: 49834X 10 6 (Check One): o Form 10-K o Form 20-F o Form 11-K þ Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: June 30, 2010 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-
July 27, 2010	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF EARLIEST REPORTED EVENT: July 26, 2010 KIWA BIO-TECH PRODUCTS GROUP CORPORATION (Exact name of Registrant as specified in its charter) Delaware 000-33167 77-0632186 (State or other jurisdiction (Commission File Number) (IRS E
July 20, 2010	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF EARLIEST REPORTED EVENT: July 19, 2010 KIWA BIO-TECH PRODUCTS GROUP CORPORA UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF EARLIEST REPORTED EVENT: July 19, 2010 KIWA BIO-TECH PRODUCTS GROUP CORPORATION (Exact name of Registrant as specified in its charter) Delaware 000-33167 77-0632186 (State or other jurisdiction (Commission File Number) (IRS E
July 20, 2010	EX-16.1	EX-16.1
May 13, 2010	10-Q	UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2010 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-33167 KIWA BIO-TECH PRODUCTS
March 29, 2010	10-K	UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2009 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number: 000-33167 KIWA BIO-TECH PRODUCTS GROUP
December 22, 2009	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2009 KIWA BIO-TECH PRODUCTS GROUP CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-33167 77-0632186 (State or other jurisdiction of incorpo
November 20, 2009	DEF 14A	UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State
November 12, 2009	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q R QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2009 ¨ TRANSITION REPORT PURSUANT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q R QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2009 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-33167 KIWA BIO-TECH PRODU
November 3, 2009	PRER14A	UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 2) Filed by the Registrant R Filed by a Party other than the Registrant ¨ Check the appropriate box: R Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defi
November 3, 2009	CORRESP	November 3, 2009 November 3, 2009 Mr. H. Roger Schwall Division of Corporation Finance United States Securities and Exchange Commission Washington, D.C. 20549-4628 Re: Kiwa Bio-Tech Products Group Corporation Preliminary Proxy Statement, Amendment No. 1 Filed September 25, 2009 Form 10-K/A for the Fiscal year Ended December 31, 2008 Filed September 25, 2009 Form 10-Q/A for the Fiscal Quarter Ended March 31, 2009 F
September 25, 2009	10-K/A	UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2008 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number: 000-33167 KIWA BIO-T
September 25, 2009	CORRESP	September 24, 2009 September 24, 2009 Mr. Norman W. Gholson Division of Corporation Finance Securities and Exchange Commission Re: SEC comments on Kiwa Bio-Tech Products Group Corporation Preliminary Proxy Statement Filed July 29, 2009 Form 10-K for the Fiscal Year Ended December 31, 2008 Filed May 18, 2009 Form 10-Q for the Fiscal Quarter Ended March 31, 2009 Filed June 15, 2009 File No. 0-33167 Dear Mr. Norman: Th
September 25, 2009	10-Q/A	UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment No. 1 R QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2009 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-33167 KIWA B
September 25, 2009	10-Q/A	UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment No. 1 R QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2009 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-33167 KIWA
September 25, 2009	PRER14A	UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant R Filed by a Party other than the Registrant ¨ Check the appropriate box: R Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defi
September 3, 2009	CORRESP	KIWA BIO-TECH PRODUCTS GROUP CORPORATIOIN 310 North Indian Hill Blvd., #702 Claremont, CA 91711 September 3, 2009 KIWA BIO-TECH PRODUCTS GROUP CORPORATIOIN 310 North Indian Hill Blvd., #702 Claremont, CA 91711 September 3, 2009 United States Securities and Exchange Commission Division of Corporation Finance Washington, D.C. 20549-4628 Attn: Mr. H. Roger Schwall Re: Kiwa Bio-Tech Products Group Corporation Preliminary Proxy Statement File July 29, 2009 Form 10-K for the Fiscal Year Ended December 31, 2008 File
August 12, 2009	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q R QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2009 ¨ TRANSITION REPORT PURSUANT TO S UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q R QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2009 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-33167 KIWA BIO-TECH PRODUCTS G
July 29, 2009	PRE 14A	UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant To Section 14(A) Of The Securities Exchange Act Of 1934 Filed by the Registrant R Filed by a Party other than the Registrant □ Check the appropriate box: R Preliminary Proxy Statement □ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) □ Definitive Proxy State
June 15, 2009	10-Q	UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q R QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2009 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-33167 KIWA BIO-TECH PRODUCTS
June 9, 2009	8-K	Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 3, 2009 Date of Report (Date of earliest event reported) KIWA BIO-TECH PRODUCTS GROUP CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-33167 77-0632186 (State or other jurisdiction of incorporation
June 8, 2009	EX-16.1	June 7, 2009 June 7, 2009 Security and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Re: Kiwa Bio-Tech Products Group Corporation We have read Item 4.01 of the Form 8-K dated June 2, 2009 of Kiwa Bio-Tech Products Group Corporation and are in agreement with the statements that relates to us. We previously informed the registrant that we would not stand for reappointment for 2009 audit services un
June 8, 2009	8-K	UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 2, 2009 Date of Report (Date of earliest event reported) KIWA BIO-TECH PRODUCTS GROUP CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-33167 77-0632186 (State or other jurisdiction of incorporation
May 18, 2009	10-K	UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2008 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number: 000-33167 KIWA BIO-TECH PRODUCTS GROUP
May 18, 2009	EX-3.3	CERTIFICATE OF AMENDMENT CERTIFICATE OF INCORPORATION KIWA BIO-TECH PRODUCTS GROUP CORPORATION Exhibit 3.3 CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION OF KIWA BIO-TECH PRODUCTS GROUP CORPORATION Kiwa Bio-Tech Products Group Corporation (the “Company”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify: FIRST: That pursuant to the unanimous written consent of the Board of Directors of the Company
May 18, 2009	EX-14.1	Kiwa Bio-Tech Products Group Corporation Code of Business Conduct and Ethics January 2005 Exhibit 14.1 Kiwa Bio-Tech Products Group Corporation Code of Business Conduct and Ethics January 2005 Introduction This Code of Business Conduct and Ethics (the "Code") embodies the commitment of Kiwa Bio-Tech Products Group Corporation and its subsidiaries to conduct our business in accordance with all applicable laws, rules and regulations and the highest ethical standards. All employees and me
February 19, 2009	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 18, 2009 KIWA BIO-TECH PRODUCTS GROUP CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-33167 77-0632186 (State or other jurisdiction of incorpo
February 19, 2009	EX-10.1	EMPLOYMENT AGREEMENT EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT is made and entered into this 25th day of February 18, 2009 by and between Kiwa Bio-tech Products Group Corp.
February 3, 2009	8-K	UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 2, 2009 Date of Report (Date of earliest event reported) KIWA BIO-TECH PRODUCTS GROUP CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-33167 77-0632186 (State or other jurisdiction of incorpora
February 3, 2009	EX-10.1	EMPLOYMENT AGREEMENT EX-10.1 2 v138635ex10-1.htm EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT is made and entered into this 2nd day of February, 2009 by and between Kiwa Bio-tech Products Group Corp., a Delaware corporation having its principal place of business at 310 N. Indian Hill Blvd., #702 Claremont, California and Li Wei, an individual, whose address is 6 Hao Lou, #1805, Dao Xiang Yuan, Hai Dian Qu, Beijing,
January 14, 2009	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 12, 2009 Date of Report (Date of earliest event reported) KIWA BIO-TECH PRODUCTS GROUP CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-33167 77-0632186 (State or other jurisdiction of incorpora
January 7, 2009	8-K	UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 4, 2009 Date of Report (Date of earliest event reported) KIWA BIO-TECH PRODUCTS GROUP CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-33167 77-0632186 (State or other jurisdiction of incorporat
November 19, 2008	DEFR14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Amendment No. 1) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Amendment No. 1) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant þ Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) þ Defi
November 13, 2008	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant þ Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) þ Definitive Proxy State
November 12, 2008	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2008 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-33167 KIWA BIO-TECH PRODU
November 12, 2008	EX-10.3	TERM SHEET FOR REDEMPTION OF CONVERTIBLE NOTES TERM SHEET FOR REDEMPTION OF CONVERTIBLE NOTES This Term Sheet is entered into by and among Kiwa Bio-Tech Products Group Corporation (the ?Company?) and AJW Offshore Ltd.
November 12, 2008	EX-10.4	TERM SHEET FOR REDEMPTION OF CONVERTIBLE NOTES EX-10.4 5 v131603ex10-4.htm TERM SHEET FOR REDEMPTION OF CONVERTIBLE NOTES This Term Sheet is entered into by and among Kiwa Bio-Tech Products Group Corporation (the “Company”) and FirsTrust Group, Inc. (the “FirsTrust Group.”) as of October 7, 2008. WHEREAS, the Company issued to Nite Capital LP Callable Secured Convertible Notes (the “6% Notes”), pursuant to a Securities Purchase Agreement dated
October 28, 2008	PRER14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant þ Filed by a Party other than the Registrant ¨ Check the appropriate box: þ Preliminary Proxy Statement ¨ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State
October 27, 2008	CORRESP	KIWA BIO-TECH PRODUCTS GROUP CORPORATION KIWA BIO-TECH PRODUCTS GROUP CORPORATION October 27, 2008 H. Roger Schwall, Assistant Director, Division of Corporation Finance Securities and Exchange Commission Mail Stop 7010 Washington, D.C. 20549 Re: Kiwa Bio-Tech Products Group Corporation Form Schedule 14A - Preliminary Proxy Statement Filed September 23, 2008 File No. 0-33167 Dear Mr. Schwall: Kiwa Bio-Tech Products Group Corporation (the
September 23, 2008	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant þ Filed by a Party other than the Registrant ¨ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State
September 22, 2008	CORRESP	K I W A B I O - T E C H P R O D U C T S G R O U P C O R P O R A T I O N K I W A B I O - T E C H P R O D U C T S G R O U P C O R P O R A T I O N September 22, 2008 Karl Hiller, Securities and Exchange Commission Division of Corporate Finance Mail Stop 7010 Washington, D.
September 22, 2008	10KSB/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-KSB/A Amendment No. 2 ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2007 Commission File Numbe UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-KSB/A Amendment No. 2 ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2007 Commission File Number: 000-33167 KIWA BIO-TECH PRODUCTS GROUP CORPORATION (Name of small business issuer in its charter) Delaware 77-0632186 (State or other jurisdiction
September 10, 2008	CORRESP	Very truly yours, Kiwa Bio-Tech Products Group Corporation By: /s/ Lianjun Luo Lianjun Luo Chief Financial Officer September 10, 2008 Karl Hiller, Securities and Exchange Commission Division of Corporate Finance Mail Stop 7010 Washington, D.
August 11, 2008	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2008 o TRANSITION REPORT PURSUANT TO S UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2008 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-33167 KIWA BIO-TECH PRODUCTS G
August 11, 2008	EX-10.1	CONSULTING AGREEMENT EX-10.1 3 v122689ex10-1.htm CONSULTING AGREEMENT This CONSULTING AGREEMENT (the "Agreement"), is effective as January 1, 2008, between: Mr. Robert Schechter at Equity Communications (the “Consultant”), with an office at 551 Fifth Ave. #3025 New York, NY 10176 and KIWA Bio-Tech Products Group Corporation, ("Company"), with offices at 415 W. Foothill Blvd., #206 Claremont CA 91711 WITNESSETH WHEREAS
August 6, 2008	CORRESP	KIWA BIO-TECH PRODUCTS GROUP CORPORATION KIWA BIO-TECH PRODUCTS GROUP CORPORATION August 6, 2008 Karl Hiller, Securities and Exchange Commission Division of Corporate Finance Mail Stop 7010 Washington, D.
August 6, 2008	10KSB/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-KSB/A Amendment No. 1 ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2007 Commission File Numbe UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-KSB/A Amendment No. 1 ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2007 Commission File Number: 000-33167 KIWA BIO-TECH PRODUCTS GROUP CORPORATION (Name of small business issuer in its charter) Delaware 77-0632186 (State or other jurisdiction
May 27, 2008	EX-10.01	Contract for Joint Venture Hebei Huaxing Pharmaceuticals Co., Ltd. Kiwa Bio-Tech Products Group Corporation Chapter 1 General Rules Contract for Joint Venture Between Hebei Huaxing Pharmaceuticals Co., Ltd. And Kiwa Bio-Tech Products Group Corporation Chapter 1 General Rules According to “Law of the People's Republic of China on Chinese-Foreign Joint Ventures,” “Company Law of the People’s Republic of China” and other applicable regulations and based on principles of equality and mutual benefit, after discussion, Hebei Huaxing
May 27, 2008	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 May 22, 2008 Date of Report (Date of earliest event reported) KIWA BIO-TECH PRO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 May 22, 2008 Date of Report (Date of earliest event reported) KIWA BIO-TECH PRODUCTS GROUP CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-33167 77-0632186 (State or other jurisdiction of incorpora
May 9, 2008	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q R QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2008 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q R QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2008 □ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-33167 KIWA BIO-TECH PRODUCTS
March 26, 2008	10KSB	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-KSB ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2007 Commission File Number: 000-33167 KIWA UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-KSB ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2007 Commission File Number: 000-33167 KIWA BIO-TECH PRODUCTS GROUP CORPORATION (Name of small business issuer in its charter) Delaware 77-0632186 (State or other jurisdiction of incorporation o
February 22, 2008	EX-10.01	STOCK PURCHASE AGREEMENT STOCK PURCHASE AGREEMENT This STOCK PURCHASE AGREEMENT (this "Agreement") is made and entered into as of February 19, 2008, by and between Yuxin Zhou (ID: 440202196911110669) ("Purchaser") and KIWA BIO-TECH PRODUCTS GROUP CORPORATION (the"Company"), a company incorporated under the laws of the State of Delaware in the United States of America whose registered office is at 415 W.
February 22, 2008	8-K	Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 19, 2008 Date of Report (Date of earliest event reported) KIWA BIO-TECH PRODUCTS GROUP CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-33167 77-0632186 (State or other jurisdiction of incorpor
January 11, 2008	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 10, 2008 Date of Report (Date of earliest event reported) KIWA BIO-TECH PRODUCTS GROUP CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-33167 77-0632186 (State or other jurisdiction of incorpora
January 11, 2008	EX-10.01	Advance Agreement Advance Agreement Party A : Wei Li Party B : Kiwa Bio-Tech Products Group Corporation The Advance Agreement is signed on January 10, 2008 by both parties, to clarify the following advance transactions: 1.
November 7, 2007	EX-10.62	Advance Agreement Advance Agreement Party A: Wei Li Party B: Kiwa Bio-Tech Products (Shandong) Co., Ltd. The Advance Agreement is signed on June 30, 2007 by both parties, to clarify the following advance transactions: 1. During June 2007, Party A advanced an aggregate sum of RMB 336,432.46 (i.e. US$44,177.33) to Party B in China. 2. Both parties agreed the abovementioned advances bear interest at 6% per annum start
November 7, 2007	10QSB	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-QSB x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2007 o TRANSITION REPORT UNDER SECTIO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-QSB x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2007 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-33167 KIWA BIO-TECH PRODUCTS GROUP
November 7, 2007	EX-10.63	Advance Agreement Advance Agreement Party A: Wei Li Party B: Kiwa Bio-Tech Products Group Corporation The Advance Agreement is signed on September 10, 2007 by both parties, to clarify the following advance transactions: 1.
October 29, 2007	EX-10.2	STOCK PURCHASE AGREEMENT STOCK PURCHASE AGREEMENT Party A: Hui Chen Party B: Wei Li Party C: Kiwa Bio-Tech Products Group Corporation This Stock Purchase Agreement (this "Agreement") is made and entered into as of 24th day of October 2007, by and between Hui Chen (the ?Party A?), Wei Li (the ?Party B?) and Kiwa Bio-Tech Products Group Corporation (the ?Company?), a company incorporated under the laws of the State of Delaware in the United States of America whose registered office is at 415 W.
October 29, 2007	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 24, 2007 Date of Report (Date of earliest event reported) KIWA BIO-TECH PRODUCTS GROUP CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-33167 77-0632186 (State or other jurisdiction (Commission
October 29, 2007	EX-10.1	STOCK PURCHASE AGREEMENT EX-10.1 2 v091479ex10-1.htm STOCK PURCHASE AGREEMENT Party A: Kexin Xiao Party B: Wei Li Party C: Kiwa Bio-Tech Products Group Corporation This Stock Purchase Agreement (this "Agreement") is made and entered into as of 24th day of October 2007, by and between Kexin Xiao (the “Party A”), Wei Li (the “Party B”) and Kiwa Bio-Tech Products Group Corporation (the “Company”), a company incorporated unde
August 14, 2007	EX-10.59	TERMINATION AGREEMENT TERMINATION AGREEMENT This Termination Agreement is made and entered into effective as of July 15th, 2007, by and between Kiwa Bio-Tech Products Group Ltd.
August 14, 2007	EX-10.61	TERMINATION AGREEMENT EX-10.61 5 v084707ex10-61.htm TERMINATION AGREEMENT This Termination Agreement is made and entered into effective as of July 22, 2007, by and between Kiwa Bio-Tech Products Group Ltd. (the “Company”) and UPB International Sourcing Limited (“UPB”) for the termination of the contract in connection with issuance of L/C dated on August 8, 2006, as amended on August 20, 2006 (the “Contract”). WHEREAS,
August 14, 2007	10QSB	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-QSB QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2007 TRANSITION REPORT UNDER SECTION 13 OR 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-QSB QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2007 TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-33167 KIWA BIO-TECH PRODUCTS GROUP CORPORATI
August 14, 2007	EX-10.60	TERMINATION AGREEMENT EX-10.60 4 v084707ex10-60.htm TERMINATION AGREEMENT This Termination Agreement is made and entered into effective as of July 18th, 2007, by and between Shengkui Technologies Inc.(the “Seller”) and Kiwa Bio-Tech Products Group Ltd. (the “Buyer”) for the termination of Sale and Purchase of Prilled Urea 46% N Agricultural Grade Contract dated July 31, 2006 (the “Contract”). WHEREAS, on July 31, 2006,
July 11, 2007	RW	July 11, 2007 July 11, 2007 VIA EDGAR AND FACSIMILE U.S. Securities and Exchange Commission Division of Corporation Finance, AD-9 100 F Street, NE Washington, D.C. 20549-3561 Re: Kiwa Bio-Tech Products Group Corporation Application for Withdrawal of Amendment No. 2 to Registration Statement on Form SB-2 SEC File No.: 333-130943 Ladies and Gentlemen: Pursuant to Rule 477 of the Securities Act of 1933, as amended
July 11, 2007	POS AM	As filed with the Securities and Exchange Commission on July 11, 2007. Registration No. 333-136572 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM SB-2 REGISTRATION STATEMENT UNDER THE SE As filed with the Securities and Exchange Commission on July 11, 2007. Registration No. 333-136572 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM SB-2 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 KIWA BIO-TECH PRODUCTS GROUP CORPORATION (Name of small business issuer in its charter) Delaware 8731 77-0632186 (State or jurisd
June 29, 2007	SB-2/A	As filed with the Securities and Exchange Commission on June 29, 2007. Registration No. 333-136572 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO.2 TO FORM SB-2 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF As filed with the Securities and Exchange Commission on June 29, 2007. Registration No. 333-136572 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO.2 TO FORM SB-2 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 KIWA BIO-TECH PRODUCTS GROUP CORPORATION (Name of small business issuer in its charter) Delaware 8731 77-0632186 (State or jurisdiction of incorp
June 18, 2007	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State
June 6, 2007	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State

KWBT / Kiwa Bio-Tech Products Group Corp. - SEC-arkiveringer, Årsrapport, Fullmaktsdokument

Grunnleggende statistikk

SEC Filings

SEC Filings (Chronological Order)